Diabetic Dyslipidemia and Atherosclerosis

Clinical Cornerstone

Volumn 9, Issue SUPPL. 2, 2008, Pages

  Davis, Stephen N ^a  

^a Division of Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEGLITINIDE; METFORMIN; MEVINOLIN; MURAGLITAZAR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TESAGLITAZAR; TORCETRAPIB; UNINDEXED DRUG;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LOW DRUG DOSE; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 65349151301     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)60022-3     Document Type: Article

References (58)

1. Krentz A.J. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 5 Suppl 1 (2003) S19-S27
2. Stephenson J.M., Kenny S., Stevens L.K., et al. Proteinuria and mortality in diabetes: The WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 12 (1995) 149-155
3. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance. Am Heart J 150 (2005) 859-870
4. Fredrickson D.S. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 75 (1971) 471-472
5. Vergès B. Diabetic dyslipidaemia: Insights for optimizing patient management. Curr Med Res Opin 21 Suppl 1 (2005) S29-S40
6. Izkhakov E., Meltzer E., and Rubinstein A. Pathogenesis and management of diabetic dyslipidemia. Treat Endocrinol 2 (2003) 231-245
7. Turner R.C., Millns H., Neil H.A., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998) 823-828
8. Abbott R.D., Wilson P.W., Kannel W.B., and Castelli W.P. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 8 (1988) 207-211
9. Castelli W.P. Cardiovascular disease and multifactorial risk: Challenge of the 1980s. Am Heart J 106 (1983) 1191
10. Glueck C.J., Gartside P., Fallat R.W., et al. Longevity syndromes: Familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88 (1976) 941-957
11. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
12. Wilding J.P. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 24 (2007) 934-945
13. Brinton E.A. Controversies in dyslipidemias: Atheroprevention in diabetes and insulin resistance. Ann N Y Acad Sci 1055 (2005) 159-178
14. Pastromas S., Terzi A.B., Tousoulis D., and Koulouris S. Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 126 (2008) 3-12
15. de Graaf J., Hak-Lemmers H.L., Hectors M.P., et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11 (1991) 298-306
16. Hurt-Camejo E., Olsson U., Wiklund O., et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vase Biol 17 (1997) 1011-1017
17. Okura Y., Brink M., Itabe H., et al. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 102 (2000) 2680
18. Dimmeler S., Haendeler J., Galle J., et al. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the "response to injury" hypothesis. Circulation 95 (1997) 1760
19. Vink H., Constantinescu A.A., and Spaan J.A. Oxidized lipoproteins degrade the endothelial surface layer: Implications for platelet-endothelial cell adhesion. Circulation 101 (2000) 1500-1502
20. Chin J.H., Azhar S., and Hoffman B.B. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 89 (1992) 10
21. Anderson T.J., Meredith I.T., Charbonneau F., et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93 (1996) 1647
22. Mathew V., Cannan C.R., Miller V.M., et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 96 (1997) 1930
23. Hassall D.G., Owens J.S., and Bruckdorfer K.R. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J 216 (1983) 43
24. Griffin J.H., Fernandez J.A., and Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 86 (2001) 386
25. Ehara S., Ueda M., Naruko T., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955
26. Gotto Jr. A.M., and Brinton E.A. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update. J Am Coll Cardiol 43 (2004) 717
27. Rosenson R.S. Low HDL-C: A secondary target of dyslipidemia therapy. Am J Med 118 (2005) 1067
28. Oram J.F., Johnson C.J., and Brown T.A. Interaction of high density lipoprotein with its receptor on cultured fibroblasts and macrophages: Evidence for reversible binding at the cell surface with internalization. J Biol Chem 262 (1987) 2405
29. Kuhn F.E., Mohler E.R., Satler L.F., et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 68 (1991) 1425
30. Saku K., Ahmad M., Glas-Greenwalt P., and Kashyap M.L. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 39 (1985) 1
31. Griffin J.H., Kojima K., Banka C.L., et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 (1999) 219
32. Epand R.M., Stafford A., Leon B., et al. HDL and apolipo-protein A-1 protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14 (1994) 1775
33. Aoyama T., Yui Y., Morishita H., and Kawai C. Prostaglandin I(2) half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81 (1990) 1784
34. Pyorala K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care. 1997;20:1048]. Diabetes Care 20 (1997) 614-620
35. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
36. Lamendola C., Abbasi F., Chu J.W., et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 95 (2005) 189-193
37. Blaschke F., Takata Y., Caglayan E., et al. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vase Biol 26 (2006) 28-40
38. Keech A., Simes R.J., Barter P., et al., for the FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial [published corrections appear in Lancet. 2006;368:1415, 1420]. Lancet 366 (2005) 1849-1861
39. van Wijk J.P., de Koning E.J., Martens E.P., and Rabelink T.J. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vase Biol 23 (2003) 1744-1749
40. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
41. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
42. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
43. Cottrell D.A., Marshall B.J., and Falko J.M. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol 18 (2003) 301-308
44. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. TV. Engl J Med 345 (2001) 1583-1592
45. Buse J.B., Bigger J.T., Byington R.P., et al., for the ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol 99 (2007) 21i-33i
46. Ginsberg H.N., Bonds D.E., Lovato L.C., et al., for the ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007) 56i-67i
47. Goff Jr. D.C., Gerstein H.C., Ginsberg H.N., et al., for the ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 (2007) 4i-20i
48. Nesto R.W. Beyond low-density lipoprotein: Addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 5 (2005) 379-387
49. Ballantyne C.M., Houri J., Notarbartolo A., et al., for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
50. Rader D.J. Illuminating HDL-Is it still a viable therapeutic target?. N Engl J Med 357 (2007) 2180-2183
51. Nissen S.E., Tardif J.C., Nicholls S.J., et al., for the ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis [published correction appears in N Engl J Med. 2007;357:835]. N Engl J Med 356 (2007) 1304-1316
52. Barter P.J., Caulfield M., Eriksson M., et al., for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
53. Di Marzo V., Goparaju S.K., Wang L., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
54. Poirier B., Bidouard J.P., Cadrouvele C., et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
55. Steffens S., and Mach F. Cannabinoid receptors in atherosclerosis. Curr Opin Lipidol 17 (2006) 519-526
56. Scheen A.J., Finer N., Hollander P., et al., for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet 2006;368:1650]. Lancet 368 (2006) 1660-1672
57. Formulary ENews, October 14, 2008. Development of taranabant for obesity discontinued. http://www.modernmedicine.com/modernmedicine/content/printContentPopup.jsp?id=558056 Accessed October 28, 2008.
58. Addy C., Wright H., Van Laere K., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7 (2008) 68-78